Kidney function impairment/coronary artery disease/contrast-induced nephropathy Urological and Genital Diseases Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions
Conditions
Interventions
All patients undergoing cardiac catheterisation with the intention of percutaneous coronary intervention (definite PCI or catheterisation +/- PCI) that meet the inclusion criteria will be randomised t
Sponsors
Liverpool Heart and Chest Hospital NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female patients aged 18 years or over 2. Estimated glomerular filtration rate (eGFR) less than 60 ml/m (as calculated by modified Modification of Diet in Renal Disease [MDRD] equation with local laboratory correction factor)
Exclusion criteria
Exclusion criteria: 1. Patients who had coronary angiography or other procedure with contrast exposure (computed tomography pulmonary angiography [CTPA] etc.) within 2 weeks of percutaneous coronary intervention (PCI) 2. Unable to consent 3. Patient undergoing cardiac surgery 4. Cardiogenic shock 5. Unlikely to attend for follow-up blood tests 6. Presence of non-cardiac illness that might affect life expectancy 7. Any previous allergic reaction to contrast media or N-acetylcysteine (NAC)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eGFR at 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Contrast-induced nephropathy. Total duration of follow-up: 6 months. 2. eGFR at 14 days 3. Major Adverse Cardiovascular Events (MACE) ? death, myocardial infarction (MI), stroke, and repeat revascularisation. Total duration of follow-up: 6 months. 4. Renal replacement therapy. Total duration of follow-up: 6 months. | — |
Countries
United Kingdom
Outcome results
None listed